Abstract
We compared in rats with 6-hydroxydopamine (6-OHDA)-induced hemiparkinsonism the content of tumor necrosis factor (TNF)-alpha in the nigrostriatal dopaminergic region of the control side with that of the 6-OHDA-injected experimental side, and explored the effects of 6-OHDA injection combined with the immunosuppressant FK506 treatment (0.5 or 4 mg/kg per day for 2 weeks). The ratios of the concentration of TNF-alpha in the striatum and substantia nigra on the 6-OHDA injection side to that on the control side in the 6-OHDA hemiparkinsonism rats were significantly higher than those in the control rats without 6-OHDA treatment, whereas those in the rats treated with 6-OHDA and FK506 were not significantly different from those in the control rats. Thus FK506 attenuated increased TNF-alpha level in the nigrostriatal dopaminergic region injured by 6-OHDA treatment.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Dopamine / metabolism
-
Functional Laterality / drug effects
-
Functional Laterality / physiology
-
Immunosuppressive Agents / pharmacology*
-
Male
-
Neostriatum / drug effects
-
Neostriatum / immunology*
-
Neostriatum / physiopathology
-
Neural Pathways / drug effects
-
Neural Pathways / immunology*
-
Neural Pathways / physiopathology
-
Neurons / drug effects
-
Neurons / metabolism
-
Neurons / pathology
-
Neuroprotective Agents / pharmacology
-
Oxidopamine / adverse effects
-
Parkinsonian Disorders / chemically induced
-
Parkinsonian Disorders / drug therapy*
-
Parkinsonian Disorders / immunology*
-
Parkinsonian Disorders / physiopathology
-
Rats
-
Rats, Sprague-Dawley
-
Substantia Nigra / drug effects
-
Substantia Nigra / immunology*
-
Substantia Nigra / physiopathology
-
Tacrolimus / pharmacology*
-
Tumor Necrosis Factor-alpha / drug effects*
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Immunosuppressive Agents
-
Neuroprotective Agents
-
Tumor Necrosis Factor-alpha
-
Oxidopamine
-
Dopamine
-
Tacrolimus